Near-infrared photoimmunotherapy with galactosyl serum albumin in a model of diffuse peritoneal disseminated ovarian cancer
- PMID: 27765903
- PMCID: PMC5340234
- DOI: 10.18632/oncotarget.12710
Near-infrared photoimmunotherapy with galactosyl serum albumin in a model of diffuse peritoneal disseminated ovarian cancer
Abstract
Near-infrared photoimmunotherapy (NIR-PIT) is a highly cell-selective cancer therapy based on an armed antibody conjugated with a phthalocyanine-based photo-absorber, IRDye700DX (IR700). NIR-PIT can quickly kill target cells that express specific proteins on the cellular membrane but only when the antibody-IR700 conjugate binds to the cell membrane and is then exposed to NIR light. NIR-PIT is highly selective based on the specificity of the antibody. Galactosyl serum albumin (GSA) is composed of albumin decorated with galactose molecules conjugated to the carboxyl groups of albumin. GSA binds to beta-D-galactose receptors, a surface lectin, which are overexpressed on the cell surface of many cancers, including ovarian cancers and is quickly internalized after binding. Here, we demonstrate the feasibility of NIR-PIT in a model of disseminated peritoneal ovarian cancer (SHIN3 cells) using GSA-IR700 that binds to beta-D-galactose receptors. GSA-IR700 bound quickly to SHIN3 cells, then accumulated in the endo-lysosomes. Cell-specific killing was observed in vitro, yet a relatively large dose of NIR light exposure was required for cell killing compared to antibody-IR700 conjugates. To evaluate in vivo therapeutic effects of GSA-IR700 NIR-PIT, peritoneal disseminated SHIN3 tumor-bearing mice were separated into four groups: no treatment; NIR light only; GSA-IR700 only; and GSA-IR700 NIR-PIT. Repeated NIR-PIT showed significant suppression of tumor based on bioluminescence compared to the other groups (p < 0.05). Thus, repeated NIR-PIT using GSA-IR700 can achieve efficient antitumor effects, although GSA-IR700 NIR-PIT was less effective than antibody-IR700 NIR-PIT conjugates likely due to the rapid internalization of GSA-IR700.
Keywords: beta-D-galactose receptor; galactosyl serum albumin; near-infrared photoimmunotherapy; ovarian cancer; peritoneal cancer metastases.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures



Similar articles
-
Near infrared photoimmunotherapy in the treatment of disseminated peritoneal ovarian cancer.Mol Cancer Ther. 2015 Jan;14(1):141-50. doi: 10.1158/1535-7163.MCT-14-0658. Epub 2014 Nov 21. Mol Cancer Ther. 2015. PMID: 25416790 Free PMC article.
-
Near-Infrared Photochemoimmunotherapy by Photoactivatable Bifunctional Antibody-Drug Conjugates Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancer.Bioconjug Chem. 2017 May 17;28(5):1458-1469. doi: 10.1021/acs.bioconjchem.7b00144. Epub 2017 Apr 26. Bioconjug Chem. 2017. PMID: 28402624 Free PMC article.
-
Near infrared photoimmunotherapy using a fiber optic diffuser for treating peritoneal gastric cancer dissemination.Gastric Cancer. 2019 May;22(3):463-472. doi: 10.1007/s10120-018-0871-5. Epub 2018 Aug 31. Gastric Cancer. 2019. PMID: 30171392 Free PMC article.
-
Near-Infrared Photoimmunotherapy of Cancer.Acc Chem Res. 2019 Aug 20;52(8):2332-2339. doi: 10.1021/acs.accounts.9b00273. Epub 2019 Jul 23. Acc Chem Res. 2019. PMID: 31335117 Free PMC article. Review.
-
Antibody Drug Conjugates of Near-Infrared Photoimmunotherapy (NIR-PIT) in Breast Cancers.Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338221145992. doi: 10.1177/15330338221145992. Technol Cancer Res Treat. 2023. PMID: 36734039 Free PMC article. Review.
Cited by
-
Optical and x-ray technology synergies enabling diagnostic and therapeutic applications in medicine.J Biomed Opt. 2018 Oct;23(12):1-17. doi: 10.1117/1.JBO.23.12.121610. J Biomed Opt. 2018. PMID: 30350489 Free PMC article. Review.
-
Simultaneously Combined Cancer Cell- and CTLA4-Targeted NIR-PIT Causes a Synergistic Treatment Effect in Syngeneic Mouse Models.Mol Cancer Ther. 2021 Nov;20(11):2262-2273. doi: 10.1158/1535-7163.MCT-21-0470. Epub 2021 Sep 13. Mol Cancer Ther. 2021. PMID: 34518299 Free PMC article.
-
PD-L1 near Infrared Photoimmunotherapy of Ovarian Cancer Model.Cancers (Basel). 2022 Jan 26;14(3):619. doi: 10.3390/cancers14030619. Cancers (Basel). 2022. PMID: 35158887 Free PMC article.
-
Ovarian Cancer Targeted Theranostics.Front Oncol. 2020 Jan 21;9:1537. doi: 10.3389/fonc.2019.01537. eCollection 2019. Front Oncol. 2020. PMID: 32039018 Free PMC article. Review.
-
Near Infrared Photoimmunotherapy; A Review of Targets for Cancer Therapy.Cancers (Basel). 2021 May 21;13(11):2535. doi: 10.3390/cancers13112535. Cancers (Basel). 2021. PMID: 34064074 Free PMC article. Review.
References
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30. - PubMed
-
- Muggia F. Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer. Gynecol Oncol. 2009;112:275–281. - PubMed
-
- Winter WE, 3rd, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, Rubin SC, Muggia F, McGuire WP. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2008;26:83–89. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous